Russian Heart Failure Journal 2014year Pilot study of the prognostic significance for intervisit variability of clinical blood pressure in patients with low ejection fraction chronic heart failure


To access this material please log in or register

Register Authorize
2014/№6

Pilot study of the prognostic significance for intervisit variability of clinical blood pressure in patients with low ejection fraction chronic heart failure

Troitskaya E. A., Kotovskaya Yu. V., Babaeva L. A., Kobalava Zh. D.
Federal State Budgetary Educational Institution of Higher Professional Education “Russian University of Peoples’ Friendship”, Miklukho-Maklaya 6, Moscow 117198

Keywords: NT-proBNP, arterial hypertension, intervisit BP variability, prognosis, CHF


DOI: 10.18087/rhfj.2014.6.1979

Background. Evidence for importance of intervisit BP variability has been continuously growing; however, the main attention has been paid to patients with arterial hypertension (AH). Aim. To study predictors and prognostic significance of intervisit clinical BP variability in patients with stable CHF and impaired systolic function. Materials and methods. Retrospective analysis was performed for 40 patients with FC II–III stable CHF, EF <40 % and NT-proBNP >400 pmol / l, and available BP values for at least 7 visits for 18 months. Intervisit BP variability was calculated as SD of mean BP values for 7 successive visits on constant therapy. Endpoints included all-cause death; admission for CHF; MI; and stroke. Results. Data analysis was performed for 40 patients (33 males; mean age, 67.5±9.2; mean BP, 129.4±13.6 / 79.2±9.2 mm Hg; heart rate, 73.1±12.1 bpm; mean EF, 32.8±2.6 %; NT-proBNP, 2683.7±3635.4 pmol / l). Intervisit systolic BP (SBP) variability ranged from 2.3 to 16 mm Hg and diastolic BP (DBP) variability – from 1.8 to 10.3 mm Hg. Ten patients had 10 endpoints (2 deaths, 6 admissions, 1 MI, and 1 stroke). Differences in main clinico-demographic, hemodynamic, and laboratory parameters between groups with and without endpoints were absent. The groups significantly differed in intevisit SBP variability (11.9±3.64 mm Hg vs. 7.8±3.2 mm Hg, p <0.05). Mono- and multifactorial regression analyses confirmed the unfavorable prognostic significance of the intervisit SBP variability >8.7 mm Hg (RR, 1.46; 95 % CI, 1.1–1.93; p=0.01; sensitivity, 90 %; specificity, 67 %, AUC, 0.79). Conclusion. Individual intervisit BP variability was heterogenic in patients with compensated CHF and reduced EF despite stable therapy. Study results suggested a prognostic significance of increased intervisit SBP variability in this patient cohort.
  1. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013 Mar;10 (3):143–55.
  2. Rosner B, Polk BF. The implications of blood pressure variability for clinical and screening purposes. J Chronic Dis. 1979;32 (6):451–61.
  3. Горбунов В. М. Современные представления о вариабельности артериального давления. Рациональная фармакотерапия в кардиологии. 2012;8:810–8.
  4. Zanchetti A. Wars, war games, and dead bodies on the battlefield: variations on the theme of blood pressure variability. Stroke. 2011 Oct;42 (10):2722–4.
  5. Poulter NR, Wedel H, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005 Sep 10–16;366 (9489):907–13.
  6. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375 (9718):895–905.
  7. Rothwell P. M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010 Mar 13;375 (9718):938–48.
  8. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010 Mar 13;375 (9718):906–15.
  9. Muntner P, Shimbo D, Tonelli M et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011 Feb;57 (2):160–6.
  10. Poortvliet RK, Ford I, Lloyd SM et al. Blood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One. 2012;7 (12):e52438.
  11. Rossignol P, Kessler M, Zannad F. Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens. 2013 Jan;22 (1):59–64.
  12. Okada H, Fukui M, Tanaka M et al. Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013 Jul;36 (7):1908–12.
  13. Okada H, Fukui M, Tanaka M et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis. 2012 Jan;220 (1):155–9.
  14. Yildiran T, Koc M, Bozkurt A et al. Low pulse pressure as a predictor of death in patients with mild to advanced heart failure. Tex Heart Inst J. 2010;37 (3):284–90.
  15. Raphael CE, Whinnett ZI, Davies JE et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009 Jan;95 (1):56–62.
  16. Ather S, Chan W, Chillar A et al. Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. Am Heart J. 2011 Mar;161 (3):567–73.
  17. Guder G, Frantz S, Bauersachs J et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic be­nefit of classical cardiovascular risk factors. Circ Heart Fail. 2009 Nov;2 (6):563–71.
  18. Radaelli A, Perlangeli S, Cerutti MC et al. Altered blood pressure variability in patients with congestive heart failure. J Hypertens. 1999 Dec;17 (12 Pt 2):1905–10.
  19. Portaluppi F, Montanari L, Ferlini M et al. Differences in blood pressure regulation of congestive heart failure, before and after treatment, correlate with changes in the circulating pattern of atrial natriuretic peptide. Eur Heart J. 1992 Jul;13 (7):990–6.
  20. Giles TD, Roffidal L, Quiroz A et al. Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure. J Cardiovasc Pharmacol. 1996 Dec;28 (6):733–40.
  21. Gibelin P, Spillner E, Bonnan S, Chevallier T. Non-invasive blood pressure variability in chronic heart failure: characteristics and prognostic value. Arch Mal Coeur Vaiss. 2003 Oct;96 (10):955–62.
  22. Mena L, Pintos S, Queipo NV et al. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005 Mar;23 (3):505–11.
  23. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006 Jan;27 (1):65–75.
  24. Grassi G, Bombelli M, Brambilla G et al. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. Curr Hypertens Rep. 2012 Aug;14 (4):333–8.
  25. Corino VDA, Mainardi LT, Belletti S, Lombardi F. Spectral analysis of blood pressure variability in atrial fibrillation. Computers in Cardiology 2008;35:833–6.
  26. Pagonas N, Schmidt S, Eysel J et al. Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension. 2013 Sep;62 (3):579–84.
Troitskaya E. A., Kotovskaya Yu. V., Babaeva L. A. et al. Pilot study of the prognostic significance for intervisit variability of clinical blood pressure in patients with low ejection fraction chronic heart failure. Russian Heart Failure Journal. 2014;15 (6):361–368

To access this material please log in or register

Register Authorize
Ru En